Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RAS protein activator like 3 (RASAL3) is an enzyme in the Ras GTPase-activating protein family that negatively regulates the Ras signaling pathway by accelerating the hydrolysis of GTP bound to Ras, inactivating Ras proteins. It contains several domains, including pleckstrin homology (PH), C2, and RasGAP domains, and localizes near or at the plasma membrane. RASAL3 is important in immune cell (natural killer T cell) expansion and function, and reduced expression is linked to increased Ras activity. Dysregulation of RASAL3 is implicated in certain proliferative and developmental disorders, including epiphyseal dysplasia and various cancers[1][3].
Drugs inhibiting or modifying RasGAPs would *modulate Ras signaling* pathways, generally by affecting the hydrolysis of GTP on Ras and thus Ras activity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RAS protein activator like 3 (RASAL3).